# RPTR-1-201

Source: https://onco.cc/drugs/rptr-1-201/  
OnCo record `rptr-1-201` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RPTR-1-201 is an experimental bispecific protein from Repertoire Immune Medicines, in phase 1 trials for advanced solid tumours in people with the HLA-A*02:01 tissue type.

## Summary

RPTR-1-201 is a tCR bispecific (an engineered T-cell receptor fused to an anti-CD3 domain) from Repertoire Immune Medicines. The engineered T-cell receptor binds a tumour-selective fragment presented by HLA-A*02:01 on cancer cells, and the anti-CD3 part pulls T cells in to kill them. The tumour fragment is not named publicly. Its phase 1/2 study (NCT07293754) is recruiting; the company's pipeline lists colorectal, lung, head and neck, triple-negative breast, pancreatic, gastric, urothelial, cervical and oesophageal cancers. In May 2026 the FDA granted Fast Track designation for HLA-A*02:01-positive unresectable or metastatic triple-negative breast cancer after standard treatment. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: RPTR-1-201
- Modality: TCR bispecific (an engineered T-cell receptor fused to an anti-CD3 domain)
- Mechanism: The engineered T-cell receptor binds a tumour-selective fragment presented by HLA-A*02:01 on cancer cells, and the anti-CD3 part pulls T cells in to kill them. The tumour fragment is not named publicly.

## Sources

- Repertoire pipeline: https://www.repertoire.com/programs/pipeline
- Repertoire Fast Track release, May 2026: https://www.repertoire.com/about/press-releases/repertoire-immune-medicines-announces-fda-fast-track-designation-for-its-investigational-immune-medicine-rptr-1-201
- ClinicalTrials.gov NCT07293754: https://clinicaltrials.gov/study/NCT07293754

## Connected records

- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [Repertoire Immune Medicines](https://onco.cc/companies/repertoire-immune-medicines/)
- trials: [An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors](https://onco.cc/trials/nct07293754/)

---
JSON: https://onco.cc/api/v1/entities/rptr-1-201.json